About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Frequency Therapeutics, Inc. (FREQ) Misstated the Potential of its Hearing Loss Treatment FX-322

DEADLINE APPROACHING: Robbins LLP Reminds Investors with Substantial Losses of the Upcoming Lead Plaintiff Deadline in the Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

SAN DIEGO, CA & WOBURN, MA / ACCESSWIRE / July 28, 2021 / Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) securities between November 16, 2020 and March 22, 2021. The complaint alleges claims under the Securities Exchange Act of 1934. Frequency Therapeutics is a pharmaceutical company that develops and commercializes a hearing loss treatment called "FX-322" for patients with severe sensorineural hearing loss ("SNHL").

If you purchased shares of Frequency Therapeutics, Inc. (FREQ) between November 16, 2020 and March 22, 2021, you have until August 2, 2021, to ask the court to appoint you lead plaintiff for the class. If you would like more information on how to move for lead plaintiff, please contact Lauren Levi at (800) 350-6003 or llevi@robbinsllp.com, or via our Shareholder Information Form.

Frequency Therapeutics, Inc. (FREQ) Misstated the Potential of its Hearing Loss Treatment FX-322

According to the complaint, Frequency Therapeutics began its Phase 2a trial for FX-322 in October 2019. The trial results failed to live up to the Company's expectations, as they revealed no discernable difference between FX-322 and the placebo. However, the Company continued to conduct the trial and released positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. At the same time, CEO David Lucchino sold over 350,000 shares and earned over $10.5 million in the months prior to releasing the results of the Phase 2a trial. On March 23, 2021, Frequency Therapeutics disclosed disappointing Phase 2a results, revealing that subjects with mild to moderate SNHL did not demonstrate improvements in hearing measures versus placebo. On this news, Frequency Therapeutics' shares fell 78% from $36.29 to $7.99, losing approximately $955 in market capitalization.

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Frequency Therapeutics, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

CONTACT:
Lauren Levi 
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com 
(800) 350-6003
www.robbinsllp.com

SOURCE: Robbins LLP



View source version on accesswire.com:
https://www.accesswire.com/657467/Frequency-Therapeutics-Inc-FREQ-Misstated-the-Potential-of-its-Hearing-Loss-Treatment-FX-322

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.